Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma
NCT02579824
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
14
Enrollment
OTHER
Sponsor class
Stopped
stopped prematurely
Conditions
Myeloma
Interventions
DRUG:
DS-3032b
Sponsor
M.D. Anderson Cancer Center
Collaborators
[object Object]